Published in Nat Rev Nephrol on November 23, 2010
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14
Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol (2014) 1.05
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open (2013) 1.02
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol (2011) 0.96
Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol (2014) 0.95
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol (2012) 0.86
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep (2014) 0.85
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol (2011) 0.82
Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep (2015) 0.81
Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol (2013) 0.81
Complement regulation of T-cell alloimmunity. Semin Nephrol (2013) 0.81
Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol (2014) 0.80
Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res (2014) 0.79
Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol (2015) 0.79
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) (2014) 0.77
Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations. Pediatr Nephrol (2013) 0.76
Complement related kidney diseases: Recurrence after transplantation. World J Transplant (2016) 0.75
Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J (2012) 0.75
Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States. Transplant Direct (2015) 0.75
A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep (2014) 0.75
Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol (2017) 0.75
The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Rep (2014) 0.75
Posttransplant outcome of atypical haemolytic uraemic syndrome in a patient with thrombomodulin mutation: a case without recurrence. Clin Kidney J (2015) 0.75
Complement. First of two parts. N Engl J Med (2001) 11.16
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med (2002) 3.39
Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol (2009) 3.33
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.01
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int (2001) 2.43
Post-transplant hemolytic-uremic syndrome. Kidney Int (2002) 2.39
Decay-accelerating factor modulates induction of T cell immunity. J Exp Med (2005) 2.34
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 2.23
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet (2005) 2.06
Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med (2006) 1.97
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med (2010) 1.80
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol (2008) 1.68
Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet (2009) 1.67
Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol (2009) 1.65
Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol (2006) 1.64
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet (2005) 1.59
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.55
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood (2007) 1.53
Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol (2006) 1.47
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant (2009) 1.44
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med (2001) 1.41
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol (2005) 1.40
Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis (2009) 1.39
Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant (2006) 1.37
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol (2005) 1.35
Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.34
Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis (2003) 1.34
Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis (2005) 1.31
The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 1.31
Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int (1999) 1.28
Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant (2009) 1.27
Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant (2005) 1.25
Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant (2005) 1.23
De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis (2003) 1.21
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation (2010) 1.20
Endothelial cells in allograft rejection. Transplantation (2008) 1.19
Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol (2000) 1.19
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 1.17
Thrombomodulin is present in human plasma and urine. J Clin Invest (1985) 1.17
Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol (2009) 1.16
Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J Exp Med (1987) 1.16
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2006) 1.15
Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant (2007) 1.12
Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant (2008) 1.10
Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant (2008) 1.08
The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol (2003) 1.06
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2008) 1.06
Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant (2009) 1.06
Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant (2006) 1.06
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol (2008) 1.03
De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis (1999) 1.02
Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation (1987) 1.01
Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis (2000) 0.99
A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol (2006) 0.99
Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest (1993) 0.98
Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol (2008) 0.98
De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant (2010) 0.98
Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant (2004) 0.98
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood (2007) 0.97
Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis (2010) 0.97
Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant (2010) 0.96
Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation (2003) 0.95
Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant (2009) 0.95
Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol (2004) 0.94
Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant (2009) 0.94
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation (2003) 3.79
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med (2013) 3.41
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet (2002) 2.64
Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 2.63
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol (2008) 2.30
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis (2003) 2.21
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int (2004) 2.08
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol (2012) 2.03
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet (2008) 1.93
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol (2003) 1.93
High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90
Kidney transplant in black recipients: are African Europeans different from African Americans? Am J Transplant (2005) 1.88
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis (2012) 1.84
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation (2003) 1.83
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Identification of a gene expression profile associated with operational tolerance among a selected group of stable kidney transplant patients. Transpl Int (2011) 1.73
Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int (2008) 1.71
Medication errors in hospitals: computerized unit dose drug dispensing system versus ward stock distribution system. Pharm World Sci (2003) 1.70
Multivariate analysis of donor risk factors for graft survival in kidney transplantation. Transplantation (2003) 1.69
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol (2007) 1.66
FDG-PET/CT in patients with ANCA-associated vasculitis: case-series and literature review. Autoimmun Rev (2013) 1.62
Fanconi syndrome due to deferasirox. Am J Kidney Dis (2009) 1.61
Very long-term follow-up of living kidney donors. Transpl Int (2012) 1.61
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant (2009) 1.58
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy (2008) 1.53
Kidney function following nephrectomy: similitude and discrepancies between kidney cancer and living donation. Urol Oncol (2010) 1.53
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol (2011) 1.51
Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function. Transplantation (2008) 1.50
To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation (2007) 1.49
Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant (2004) 1.48
Histologic recurrence of Henoch-Schonlein Purpura nephropathy after renal transplantation on routine allograft biopsy. Transplantation (2011) 1.47
Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant (2007) 1.46
Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods (2011) 1.46
Sirolimus therapy may cause cardiac tamponade. Transpl Int (2012) 1.43
Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int (2012) 1.42
Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics (2008) 1.41
Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation (2010) 1.41
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int (2011) 1.39
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood (2009) 1.37
The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol (2013) 1.34
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant (2003) 1.34
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood (2010) 1.31
Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol (2006) 1.29
Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol (2008) 1.29
Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant (2008) 1.27
mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) (2008) 1.22
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) (2004) 1.21
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome. J Am Soc Nephrol (2010) 1.21
Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.20
Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol (2008) 1.20
Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. Nephrol Dial Transplant (2007) 1.19
Schimke immunoosseous dysplasia: suggestions of genetic diversity. Hum Mutat (2007) 1.19
Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol (2011) 1.18
High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant (2006) 1.17
Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf (2012) 1.17
Herbs and the kidney. Am J Kidney Dis (2004) 1.16
Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2010) 1.15
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Replacement kidney lipomatosis after renal transplantation. Transplantation (2005) 1.12